Sage Therapeutics (Nasdaq: SAGE) announced that the European Medicines Agency (EMA) has granted its PRIority MEdicines (PRIME) designation to SAGE-547 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE